PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)
Primary Purpose
Insulin-dependent Gestational Diabetes
Status
Unknown status
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
vildagliptin
inactive pill
Sponsored by
About this trial
This is an interventional treatment trial for Insulin-dependent Gestational Diabetes
Eligibility Criteria
Inclusion Criteria:
- women with insulin-dependent gestational diabetes during the last pregnancy
- < 9 months after delivery
- age 18 years or older
- contraception during intervention period (at least 24 months)
Exclusion Criteria:
- pregnancy or lactation
- GADA or IA-2A positivity
- clinical overt diabetes
Sites / Locations
- Institut fuer DiabetesforschungRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
vildagliptin
inactive pill without active agent
Arm Description
participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
Outcomes
Primary Outcome Measures
development of type 2 diabetes mellitus by criteria of ADA 1997
Secondary Outcome Measures
Full Information
NCT ID
NCT01018602
First Posted
November 20, 2009
Last Updated
June 24, 2011
Sponsor
Institut fur Diabetesforschung, Munich, Germany
1. Study Identification
Unique Protocol Identification Number
NCT01018602
Brief Title
PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)
Official Title
A Phase II, Randomized, Double-blind, 2-arm Controlled Study to Evaluate Efficacy of the DPPIV-inhibitor Vildagliptin for Prevention of Type 2 Diabetes in Women With a Recent History of Insulin-requiring Gestational Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2012 (Anticipated)
Study Completion Date
June 2015 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Institut fur Diabetesforschung, Munich, Germany
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to prove the efficacy of the oral intake of vildagliptin in a daily dose of 100 mg in scope of the development of type 2 diabetes in women with insulin dependent gestational diabetes in their last pregnancy not longer than 9 months after birth.
In this randomized, placebo-controlled, double-blinded clinical phase II study, 140 participants aged 18 years or older and an insulin dependent gestational diabetes in their last pregnancy should be included and treated with vildagliptin or placebo over 24 months, followed by a 12 months observation period. Exclusion criteria are pregnancy and lactation as well as a clinical overt diabetes or islet autoimmunity.
The null hypothesis is that there is no significant difference of diabetes incidence (according to ADA criteria 1997) in both groups.
Primary endpoint is the clinical manifestation of diabetes, secondary endpoints include the improvement of beta cell function (evaluable by C-peptide measurement) and of insulin sensitivity by the treatment with vildagliptin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin-dependent Gestational Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
vildagliptin
Arm Type
Active Comparator
Arm Title
inactive pill without active agent
Arm Type
Placebo Comparator
Arm Description
participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
Intervention Type
Drug
Intervention Name(s)
vildagliptin
Intervention Description
100 mg per day over 24 months
Intervention Type
Drug
Intervention Name(s)
inactive pill
Intervention Description
1 pill per day over 24 months
Primary Outcome Measure Information:
Title
development of type 2 diabetes mellitus by criteria of ADA 1997
Time Frame
3 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
women with insulin-dependent gestational diabetes during the last pregnancy
< 9 months after delivery
age 18 years or older
contraception during intervention period (at least 24 months)
Exclusion Criteria:
pregnancy or lactation
GADA or IA-2A positivity
clinical overt diabetes
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anette G Ziegler, MD
Phone
+49 (0)89 3068 2917
Ext
2917
Email
anziegler@lrz.uni-muenchen.de
Facility Information:
Facility Name
Institut fuer Diabetesforschung
City
Munich
ZIP/Postal Code
80804
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anette G Ziegler, MD
Phone
+49 (0)89 3068 2917
Ext
2917
Email
anziegler@lrz.uni-muenchen.de
First Name & Middle Initial & Last Name & Degree
Anette G Ziegler, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
29396374
Citation
Hummel S, Beyerlein A, Pfirrmann M, Hofelich A, Much D, Hivner S, Bunk M, Herbst M, Peplow C, Walter M, Kohn D, Hummel N, Kratzsch J, Hummel M, Fuchtenbusch M, Hasford J, Ziegler AG; PINGUIN Study Group. Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. Mol Metab. 2018 Mar;9:168-175. doi: 10.1016/j.molmet.2017.12.015. Epub 2018 Jan 3.
Results Reference
derived
Learn more about this trial
PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)
We'll reach out to this number within 24 hrs